Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women

Hypertension

Volumn 28, Issue 3, 1996, Pages 330-334

  Sudhir, Krishnankutty ^a,b   Jennings, Garry L ^a   Funder, John W ^a   Komesaroff, Paul A ^a  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

endothelium, vascular; estrogens; menopause; nitric oxide; plethysmography

Indexed keywords

ACETYLCHOLINE; ESTRADIOL VALERATE; ESTROGEN; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; FOREARM BLOOD FLOW; HEART PROTECTION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029816542     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.3.330     Document Type: Article

References (37)

1. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab. 1987;65:1231-1237.
2. Colditz GA, Willett WC, Stampfer MJ, Rosner N, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
3. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
4. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program follow-up study. Circulation. 1987; 75:1102-1109.
5. Ingegno MD, Money SR, Thelmo W, Greene GL, Davidian M, Jaffe BM, Pertschul LP. Progesterone receptors in the human heart and great vessels. Lab Invest. 1988;59:353-356.
6. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol. 1991;104:1033-1037.
7. Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, Chatterjee K. Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol. 1995;26:807-814.
8. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation. 1994;90:786-791.
9. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994;89:2545-2551.
10. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 1994;89:52-60.
11. Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17β-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 1995;92:24-30.
12. Williams JK, Adams MR, Klopfenstein HB. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990;81: 1680-1687.
13. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-941.
14. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
15. Sudhir K, Esler MD, Jennings GL, Komesaroff PA. Estrogen supplementation attenuates norepinephrine induced vasoconstriction in the forearm vasculature in perimenopausal women. Circulation. 1995;92(suppl I):I-421. Abstract.
16. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A. 1992;89:11259-11263.
17. Van Buren G, Yang D, Clark KE. Estrogen-induced uterine vasodilation is antagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide synthesis. Am J Obstet Gynecol. 1992;16:828-833.
18. Schray-Utz B, Zeiher AM, Busse R. Expression of constitutive NO synthase in cultured endothelial cells is enhanced by 17β-estradiol. Circulation. 1993;88(suppl I):I-80. Abstract.
19. Sayegh HS, Ohara Y, Navas JP, Peterson TE, Dockery S, Harrison DG. Endothelial nitric oxide synthase regulation by estrogens. Circulation. 1993;88(suppl I):I-80. Abstract.
20. Roselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: a 2-year followup study. Hypertension. 1995;25:848-853.
21. Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Cin Invest. 1989;83:1774-1777.
22. Bath PM, Hassall DG, Gladwin AM, Palmer RM, Martin JF. Nitric oxide and prostacyclin: divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb. 1991;11:254-260.
23. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057-1058.
24. Weiss NS. Relationship of menopause to serum cholesterol and arterial blood pressure: the United States Health Examination Survey of adults. Am J Epidemiol. 1972;96:237-241.
25. Crane MG, Harris JJ, Winsor W. Hypertension, oral contraceptive agents and conjugated estrogens. Ann Intern Med. 1971;74:13-21.
26. Pfeffer RI. Estrogen use, hypertension and stroke in post-menopausal women. J Chron Dis. 1978;31:389-398.
27. Wren BG, Brown LB, Routledge DA. Differential clinical response to oestrogens after menopause. Med J Aust. 1982;2:329-332.
28. Barrett-Connor E, Wingard DL, Criqui MH. Post-menopausal estrogen use and heart disease risk factors in the 1980's. JAMA. 1989; 261:2095-2100.
29. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
30. Pallas KG, Holzwarth GJ, Stern MP, Lucas CP. The effect of conjugated estrogens on the renin-angiotensin system. J Clin Endocrinol Metab. 1977;44:1061-1068.
31. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynaecol. 1979;54:74-79.
32. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990; 86:228-234.
33. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 1993;341:1496-1500.
34. Roberts DH, Tsao Y, Breckenridge AM. The reproducibility of limb blood flow measurements in human volunteers at rest and after exercise by using mercury-in-Silastic strain gauge plethysmography under standardized conditions. Clin Sci. 1986;70:635-638.
35. Bassett DR Jr, Duey WJ, Walker AJ, Howley ET, Bond V. Racial differences in maximal vasodilatory capacity of forearm resistance vessels in normotensive young adults. Am J Hypertens. 1992;5: 781-786.
36. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 1995;25:918-923.
37. Pedrinelli R, Taddei S, Salvetti A. Calcium entry blockade and alpha-adrenergic vascular reactivity in human beings: differences between nicardipine and verapamil. Clin Pharmacol Ther. 1989;45:285-290.